Ethris and EIB Sign €30M Financing for Antiviral
Munich, Germany, September 10, 2026 Ethris GmbH and the European Investment Bank (EIB) have signed a €30 million financing...
FDA Fast Track
Advertisement
Adagene and Third Arc Bio Select First Lead Candidate
San Diego, California, and Suzhou, China, September 10, 2026 Adagene Inc. and Third Arc Bio, Inc. have announced the...
Consano Bio Reports C-1101 Data in Chronic Sciatica
Burlington, Massachusetts, U.S., September 10, 2026 Consano Bio, Inc. has announced the publication of peer-reviewed nonclinical research evaluating C-1101,...
Verastem Oncology Advances VS-7375 Across KRAS G12D Cancers
BOSTON, Massachusetts — September 8, 2026 Verastem Oncology announced plans to host an investor event and webcast on October...
Opus Genetics to Present OPGx-BEST1 Phase 1/2 Data
RESEARCH TRIANGLE PARK, N.C., September 2, 2026 Opus Genetics, Inc. plans to present topline clinical data from Cohort 1...
Advertisements
Teva Reports Positive Phase 2a Results for TEV ‘408 in Celiac Disease
TEL AVIV, Israel, September 2, 2026 Teva Pharmaceutical Industries Ltd. has reported positive topline results from its ongoing Phase...
Polaryx Advances SOTERIA Phase 2 Trial Readiness
PARAMUS, N.J. – August 25, 2026 Polaryx Therapeutics, Inc. announced continued operational progress toward initiating its SOTERIA Phase 2...
Cellenkos Wins FDA Fast Track for CK0803 in ALS
Houston, Texas, Aug 27, 2026 Cellenkos, Inc. has received FDA Fast Track designation for CK0803, an investigational allogeneic, cord...
Rein Therapeutics Gains FDA Fast Track for LTI-03 in IPF
Austin, Texas, August 20, 2026 Rein Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
BlossomHill Therapeutics Gains FDA Fast Track for BH-30643
San Diego, California, August 18, 2026 BlossomHill Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
